ATII Holdings Inc.'s prospectus covers up to 251,510,000 common shares and 11,920,000 warrants as part of a proposed Business combination. If completed, trust-account funds can pay properly exercising public shareholders, Transaction Costs and Working Capital and general corporate purposes of Pubco and Forge Nano.
Key Highlights
- The proposed transaction includes $231,150,000 initially placed into the trust account from IPO and private-unit proceeds.
- Archimedes III issued 27,600,000 units in January 2026, including 3,600,000 units from full exercise of its over-allotment option.
- The transaction combines Archimedes Tech SPAC Partners II Co. with its wholly owned Delaware subsidiary, ATII Holdings Inc. with the Subsidiary surviving.
- The trust account held approximately $245,648,350 as of the Record Date for redemptions, transaction expenses, working capital, and general corporate purposes.
The transaction structure combines a Merger of Archimedes Tech SPAC Partners II Co. with its wholly owned Delaware subsidiary, ATII Holdings Inc. with the subsidiary surviving.
Proposed Merger Sets Security Terms
Archimedes Tech SPAC Partners II Co.’s board unanimously approved the merger and related transaction arrangements. The prospectus also serves as a proxy statement for the extraordinary general meeting. Upon completion during the Completion Window, trust-account funds are earmarked for public-share redemptions, transaction fees and expenses, working capital, and general corporate purposes of Pubco and Forge Nano. The trust account held approximately $245,648,350 as of the Record Date in an interest-bearing bank deposit account. Funds remain restricted until an initial business combination, specified charter-related Redemption events, or redemption of all public shares if no combination is completed during the Completion Window. Interest may be withdrawn to pay taxes.
Completion Triggers Deferred Underwriting Fee
BTIG, acting as representative of the IPO underwriters, is entitled to $0.35 per unit sold as a deferred fee, equal to $8,050,000 in aggregate. The transaction therefore ties the deferred underwriting payment to completion of the combination. Archimedes III issued 27,600,000 units in January 2026 and generated gross proceeds of $276,000,000, while it continues seeking a business combination target.



Please wait processing your request...